{"filing":{"accession_number":"0001213900-26-099007","cik":"0001912966","ticker":"RGNT","company_name":"REGENTIS BIOMATERIALS LTD.","form":"6-K","filing_date":"2026-09-11","report_date":"2026-06-30","primary_document":"ea0304771-6k_regentis.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1912966/000121390026099007/ea0304771-6k_regentis.htm"},"events":[{"id":32854,"run_id":30204,"accession_number":"0001213900-26-099007","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a press release dated September 11, 2026, disclosing Regentis' first-half 2026 financial results and corporate update. The exhibit reports six-month financial metrics (R\u0026D expenses of $1.2M, G\u0026A expenses of $1.2M, operating loss of $2.4M, net loss of $2.6M or $0.44 per share), cash position ($9.0M), and a $6.5M private placement completed in June 2026. While it also includes clinical and operational highlights (GelrinC® trial progress, manufacturing improvements, European expansion), the core disclosure is the interim financial results for the period ended June 30, 2026, making this an earnings release for a periodic interim reporting period.","company_name":"REGENTIS BIOMATERIALS LTD.","ticker":"RGNT","filing_date":"2026-09-11","form":"6-K","submitted_at":null,"items":[{"id":36134,"accession_number":"0001213900-26-099007","item_number":"EX-99.1","item_title":"ea030477101ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release dated September 11, 2026, disclosing Regentis' first-half 2026 financial results and corporate update. The exhibit reports six-month financial metrics (R\u0026D expenses of $1.2M, G\u0026A expenses of $1.2M, operating loss of $2.4M, net loss of $2.6M or $0.44 per share), cash position ($9.0M), and a $6.5M private placement completed in June 2026. While it also includes clinical and operational highlights (GelrinC® trial progress, manufacturing improvements, European expansion), the core disclosure is the interim financial results for the period ended June 30, 2026, making this an earnings release for a periodic interim reporting period.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T13:19:08.563344+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36134,"accession_number":"0001213900-26-099007","item_number":"EX-99.1","item_title":"ea030477101ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release dated September 11, 2026, disclosing Regentis' first-half 2026 financial results and corporate update. The exhibit reports six-month financial metrics (R\u0026D expenses of $1.2M, G\u0026A expenses of $1.2M, operating loss of $2.4M, net loss of $2.6M or $0.44 per share), cash position ($9.0M), and a $6.5M private placement completed in June 2026. While it also includes clinical and operational highlights (GelrinC® trial progress, manufacturing improvements, European expansion), the core disclosure is the interim financial results for the period ended June 30, 2026, making this an earnings release for a periodic interim reporting period.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T13:19:08.563344+00:00","company_name":"REGENTIS BIOMATERIALS LTD.","ticker":"RGNT","filing_date":"2026-09-11"},{"id":36135,"accession_number":"0001213900-26-099007","item_number":"EX-99.2","item_title":"ea030477101ex99-2.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is an unaudited interim condensed financial report for the six months ended June 30, 2026. It comprises balance sheets, statements of comprehensive loss, statements of equity, and cash flows with accompanying notes — the standard components of a periodic interim financial report. Although the company discloses substantial doubt about going concern in Note 1(c), that disclosure is embedded within the financial statements themselves, not a separate event announcement. The exhibit is the periodic report itself, which should be deferred for separate processing rather than classified as a discrete event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T13:19:08.563344+00:00","company_name":"REGENTIS BIOMATERIALS LTD.","ticker":"RGNT","filing_date":"2026-09-11"},{"id":36136,"accession_number":"0001213900-26-099007","item_number":"EX-99.3","item_title":"ea030477101ex99-3.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is an \"Operating and Financial Review and Prospects\" disclosure for the six-month period ended June 30, 2026, accompanying a 6-K filing. It presents interim financial statements, comparative results for the six months ended June 30, 2026 versus 2025, and management's discussion of operations and financial condition. This is a periodic interim financial report, not a discrete event or earnings press release. The document explicitly states it should be read \"in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K,\" confirming it is part of the periodic reporting package rather than an announcement of results.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-11T13:19:08.563344+00:00","company_name":"REGENTIS BIOMATERIALS LTD.","ticker":"RGNT","filing_date":"2026-09-11"}]}